The distinction between EV-packaged RANKL mRNA derived from breast cancer cells and the membrane-bound RANKL expressed by osteoblasts lies in both their mode of delivery and the subsequent modes of action they trigger in target cells. This evidence concerns the gene TNFSF11 and breast cancer.